Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Precigen, Inc. (NASDAQ:PGEN) has earned a consensus rating of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $7.00.

Several brokerages have recently weighed in on PGEN. HC Wainwright reiterated a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th.

Precigen Trading Down 1.1 %

NASDAQ:PGEN opened at $1.78 on Tuesday. The company has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $1.13. The company has a market cap of $521.31 million, a PE ratio of -3.24 and a beta of 1.58. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in PGEN. Envestnet Asset Management Inc. grew its holdings in Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 5,915 shares in the last quarter. Invesco Ltd. grew its stake in Precigen by 14.6% during the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 6,040 shares in the last quarter. ProShare Advisors LLC increased its holdings in Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 10,900 shares during the last quarter. Stoneridge Investment Partners LLC lifted its stake in Precigen by 21.3% in the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 12,063 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Precigen by 12.0% during the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,285 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.